KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Adding first-line PD-1 inhibition to anti-VEGF and XELOX in pMMR metastatic colorectal cancer: Steppingstones, stumbling blocks, and next phase.

Torhild Veen, Kjetil Søreide

Med 5(9) 1041-1043

PMID38964335
PMCID-
DOI10.1016/j.medj.2024.06.006
发表日期2024-07-04
摘要

摘要

In the randomized, double-blind, multicenter study by Wang et al.,1 the addition of serplulimab (a PD-1 antibody) to anti-VEGF (HLX04; a bevacizumab biosimilar) together with chemotherapy (XELOX) was deemed to be tolerable and safe and may improve progression-free survival. However, even if adverse events were comparable, oncological endpoints including survival need to be confirmed in the next phase 3 study.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。